Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT02584933 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT02584933 · ClinicalTrials.gov record · last posted 2026-06-11

Roll-over Study to Allow Access to Certinib (LDK378) for Patients Who Are on Ceritinib Treatment in a Novartis-sponsored Study

StatusActive, Not Recruiting
PhasePhase 4
Started2015-12-11
View on ClinicalTrials.gov ↗
from the ClinicalTrials.gov record
The rollover study will provide ceritinib to patients who are currently receiving treatment with ceritinib within a Novartis-sponsored study and in the opinion of the investigator, would benefit from continued treatment with ceritinib.

Amendment record 63 amendments on the ClinicalTrials.gov record

This ClinicalTrials.gov record has been amended 63 times since 2015-10-21; most recent amendment 2026-06-10. DataLookout shows field-level changes from the day a trial enters its daily monitoring; earlier amendments are counted here from the ClinicalTrials.gov version history. See every version on ClinicalTrials.gov ↗

2024-06-14
Status change Recruiting→Active, Not Recruitingv46
2016-02-10
Status change Not Yet Recruiting→Recruitingv2
Trial Details
NCT Number NCT02584933
Lead Sponsor Novartis Pharmaceuticals
Conditions ALK Positive Malignancies
Enrollment 233 participants
Start Date 2015-12-11
Primary Completion 2027-06-09 (estimated)
Study Completion 2027-06-09 (estimated)
Updated on ClinicalTrials.gov 2026-06-11